110 related articles for article (PubMed ID: 8360492)
1. Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal properties in murine macrophages.
Singh RK; Berry K; Matsushima K; Yasumoto K; Fidler IJ
J Immunol; 1993 Sep; 151(5):2786-93. PubMed ID: 8360492
[TBL] [Abstract][Full Text] [Related]
2. Synergism between human recombinant monocyte chemotactic and activating factor and lipopolysaccharide for activation of antitumor properties in human blood monocytes.
Singh RK; Fidler IJ
Lymphokine Cytokine Res; 1993 Oct; 12(5):285-91. PubMed ID: 8260537
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of anti-inflammatory cytokines (IL-4, IL-10 and IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factor.
Yano S; Sone S; Nishioka Y; Mukaida N; Matsushima K; Ogura T
J Leukoc Biol; 1995 Feb; 57(2):303-9. PubMed ID: 7852846
[TBL] [Abstract][Full Text] [Related]
4. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes.
Eue I; Kumar R; Dong Z; Killion JJ; Fidler IJ
J Immunother; 1998 Sep; 21(5):340-51. PubMed ID: 9789196
[TBL] [Abstract][Full Text] [Related]
5. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
6. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
7. Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor.
Nakano Y; Kasahara T; Mukaida N; Ko YC; Nakano M; Matsushima K
Infect Immun; 1994 Feb; 62(2):377-83. PubMed ID: 8300198
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
9. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. I. Macrophage-mediated tumor cell lysis.
Geetha B; Sodhi A
Nat Immun Cell Growth Regul; 1989; 8(2):100-7. PubMed ID: 2503714
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
11. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
12. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages.
Dong Z; Qi X; Xie K; Fidler IJ
J Immunol; 1993 Sep; 151(5):2717-24. PubMed ID: 7689614
[TBL] [Abstract][Full Text] [Related]
14. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells.
Huang S; Singh RK; Xie K; Gutman M; Berry KK; Bucana CD; Fidler IJ; Bar-Eli M
Cancer Immunol Immunother; 1994 Oct; 39(4):231-8. PubMed ID: 7954525
[TBL] [Abstract][Full Text] [Related]
15. Production of tumor necrosis factor by rIFN-gamma-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid A-associated proteins.
Hogan MM; Vogel SN
J Immunol; 1988 Dec; 141(12):4196-202. PubMed ID: 3143760
[TBL] [Abstract][Full Text] [Related]
16. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide and liposome-encapsulated MTP-PE-induced cytotoxicity and release of eicosanoids, tumor necrosis factor- alpha and nitric oxide in liver macrophages.
Dieter P; Ambs P; Fitzke E; Schwende H
Adv Exp Med Biol; 1997; 407():485-90. PubMed ID: 9321995
[No Abstract] [Full Text] [Related]
18. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma.
Bottazzi B; Walter S; Govoni D; Colotta F; Mantovani A
J Immunol; 1992 Feb; 148(4):1280-5. PubMed ID: 1737940
[TBL] [Abstract][Full Text] [Related]
19. Monocyte chemotaxis and activating factor production by keratinocytes in response to IFN-gamma.
Barker JN; Jones ML; Swenson CL; Sarma V; Mitra RS; Ward PA; Johnson KJ; Fantone JC; Dixit VM; Nickoloff BJ
J Immunol; 1991 Feb; 146(4):1192-7. PubMed ID: 1899440
[TBL] [Abstract][Full Text] [Related]
20. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
Nagao S; Sato K; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
